SOLTI-1805 TOT-HER3 trial: A window-of-opportunity trial of patritumab deruxtecan (HER3-DXd) in patients with treatment-naive, early breast cancer

被引：2

作者：

Oliveira, M. ^{[1
]}

Cejalvo Andujar, J. M. ^{[2
]}

Margeli Vila, M. ^{[3
]}

Tolosa Ortega, P. ^{[4
]}

Martinez Saez, O. ^{[5
]}

Salvador Bofill, F. J. ^{[6
]}

Cruz Jurado, J. ^{[7
]}

Barrera, A. M. Luna ^{[8
]}

Arumi De Dios, M. A. ^{[9
]}

Vidal Losada, M. J. ^{[10
]}

Guerra, J. A. ^{[11
]}

Pernas Simon, S. ^{[12
]}

Villacampa Javierre, G. ^{[13
]}

Gonzalez-Farre, B. ^{[14
]}

Sanfeliu Torres, E. ^{[14
]}

Santhanagopal, A. ^{[15
]}

Falato, C. ^{[16
]}

Ferrero Cafiero, J. M. ^{[17
]}

Pascual, T. ^{[17
]}

Prat, A. ^{[18
]}

机构：

[1] Vall Hebron Univ Hosp, Med Oncol Dept, SOLTI, Barcelona, Spain

[2] Hosp Clin Univ Valencia, Dept Med Oncol, SOLTI, Valencia, Spain

[3] Hosp Badalona Germans Trias & Pujol, ICO Inst Catala Oncol Badalona, Med Oncol Dept, SOLTI, Badalona, Spain

[4] Hosp Univ 12 Octubre, SOLTI, Oncol Dept, Valencia, Spain

[5] Hosp Clin Barcelona, SOLTI, Dept Med Oncol, Barcelona, Spain

[6] Hosp Univ Virgen Valme, Med Oncol Dept, Seville, Spain

[7] Hosp Univ Canarias, Med Oncol Dept, Santa Cruz De Tenerife, Canary Islands, Spain

[8] Hosp Clin Univ San Carlos, Med Oncol Dept, Madrid, Spain

[9] Univ Barcelona, Fac Med, Med Oncol Dept, Barcelona, Spain

[10] Hosp Clin Barcelona, SOLTI, Med Oncol Dept, Barcelona, Spain

[11] Hosp Univ Fuenlabrada, Med Oncol Dept, Fuenlabrada, Spain

[12] Hosp Duran i Reynals, Med Oncol Breast Unit, SOLTI, ICO Inst Catala Oncol Hosp, Lhospitalet De Llobregat, Spain

[13] Vall Hebron Inst Oncol VHIO, Cellex Ctr, Stat Dept, SOLTI, Barcelona, Spain

[14] Hosp Clin Barcelona, Pathol, Barcelona, Spain

[15] Daiichi Sankyo Inc, Res & Dev, Basking Ridge, NJ USA

[16] IDIBAPS August Pi i Sunyer Biomed Res Inst, Translat Genom & Targeted Therapies, Barcelona, Spain

[17] SOLTI HQ, Clin Res Dept, Barcelona, Spain

[18] Hosp Clin Barcelona, IDIBAPS, SOLTI, Dept Med Oncol, Barcelona, Spain

来源：

ANNALS OF ONCOLOGY | 2022年 / 33卷 / 07期

关键词：

D O I：

10.1016/j.annonc.2022.07.237

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

202TiP

引用

页码：S628 / S628

页数：1

共 50 条

[31] Rivaroxaban compared to no treatment in ER-negative stage I-III early breast cancer patients (the TIP Trial): study protocol for a phase II preoperative window-of-opportunity study design randomised controlled trial
Castle, John
Blower, Emma
Bundred, Nigel J.
Harvey, James R.
Thachil, Jecko
Marshall, Andrea
Cox, Karina
Cicconi, Silvia
Holcombe, Chris
Palmieri, Carlos
Kirwan, Cliona C.
TRIALS, 2020, 21 (01)
[32] A phase 3, open-label trial of neoadjuvant trastuzumab deruxtecan (T-DXd) monotherapy or T-DXd followed by THP vs ddAC-THP in high-risk HER2-positive early-stage breast cancer (DESTINY-Breast11)
Harbeck, N.
Boileau, J. -F.
Modi, S.
Kelly, C.
Ohno, S.
Wu, J.
Konpa, A.
Herbolsheimer, P.
Safdar, S.
Zhang, Y.
Pusztai, L.
BREAST, 2023, 68 : S57 - S57
[33] A phase 3, multicenter, randomized, open-label trial of trastuzumab deruxtecan (T-DXd; DS-8201) vs investigator's choice in HER2-low breast cancer (DESTINY-Breast04)
Zaman, K.
Modi, S.
Ohtan, S.
Lee, C.
Wang, Y.
Saxena, K.
Cameron, D. A.
SWISS MEDICAL WEEKLY, 2020, : 28S - 29S
[34] The SURVIVE-HERoes trial - a secondary adjuvant treatment intervention study with trastuzumab-deruxtecan in patients with HER2 positive/HER2 low early breast cancer and a molecular relapse, based on a positive ctDNA result
Huesmann, Sophia
Mergel, Franziska
Pfister, Kerstin
Fink, Angelina
Mehmeti, Forca
Moller, Peter
Fehm, Tanja
Mueller, Volkmar
Pantel, Klaus
Friedl, Thomas
Hartkopf, Andreas
Rack, Brigitte
Janni, Wolfgang
CANCER RESEARCH, 2024, 84 (09)
[35] ACE-BREAST-03: A phase 2 trial evaluating ARX788, an anti-HER2 antibody drug conjugate (ADC), for the treatment of HER2+metastatic breast cancer (mBC) in patients who have been previously treated with trastuzumab deruxtecan (T-DXd)
Tripathy, Debashish
Ali, Kashif
Agrawal, Laila
Ali, Sami M.
Blau, Sibel
Block, Margaret
Danso, Michael A.
Yardley, Denise
Andersen, Jay
Waks, Adrienne Gropper
Jayachandran, Priya
Makhlin, Igor
Nikolinakos, Petros
Zuniga, Richard
O'Shaughnessy, Joyce
Aung, Sandra
Lu, Janice M.
Kalinsky, Kevin
Gradishar, William John
Rugo, Hope S.
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[36] A phase 3, multicenter, randomized, open-label trial of [fam-] trastuzumab deruxtecan (T-DXd; DS-8201a) vs investigator's choice in HER2-low breast cancer (DESTINY-Breast04)
Modi, Shanu
Ohtani, Shoichiro
Lee, Caleb
Wang, Yibin
Saxena, Kapil
Cameron, David A.
CANCER RESEARCH, 2020, 80 (04)
[37] 6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial
Pivot, Xavier
Romieu, Gilles
Debled, Marc
Pierga, Jean-Yves
Kerbrat, Pierre
Bachelot, Thomas
Lortholary, Alain
Espie, Marc
Fumoleau, Pierre
Serin, Daniel
Jacquin, Jean-Philippe
Jouannaud, Christelle
Rios, Maria
Abadie-Lacourtoisie, Sophie
Tubiana-Mathieu, Nicole
Cany, Laurent
Catala, Stephanie
Khayat, David
Pauporte, Iris
Kramar, Andrew
LANCET ONCOLOGY, 2013, 14 (08): : 741 - 748
[38] Trastuzumab deruxtecan (T-DXd; DS-8201) vs trastuzumab emtansine (T-DM1) in high-risk patients with HER2-positive, residual invasive early breast cancer after neoadjuvant therapy: A randomized, phase 3 trial (DESTINY-Breast05)
Geyer, Charles E., Jr.
Untch, Michael
Prat, Aleix
Rastogi, Priya
Niikura, Naoki
Mathias, Elton
McLean, Lee Anne
Wang, Yibin
Loibl, Sibylle
CANCER RESEARCH, 2022, 82 (04)
[39] Trastuzumab deruxtecan (T-DXd; DS-8201) vs trastuzumab emtansine (T-DM1) in high-risk patients with HER2-positive, residual invasive early breast cancer after neoadjuvant therapy: A randomized, phase 3 trial (DESTINY-Breast05)
Geyer, Charles E., Jr.
Untch, Michael
Prat, Aleix
Rastogi, Priya
Niikura, Naoki
Mathias, Elton
McLean, Lee Anne
Wang, Yibin
Loibl, Sibylle
CANCER RESEARCH, 2021, 81 (04)
[40] Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial
Hurvitz, Sara A.
Hegg, Roberto
Chung, Wei-Pang
Im, Seock-Ah
Jacot, William
Ganju, Vinod
Chiu, Joanne Wing Yan
Xu, Binghe
Hamilton, Erika
Madhusudan, Srinivasan
Iwata, Hiroji
Altintas, Sevilay
Henning, Jan-Willem
Curigliano, Giuseppe
Perez-Garcia, Jose Manuel
Kim, Sung-Bae
Petry, Vanessa
Huang, Chiun-Sheng
Li, Wei
Frenel, Jean-Sebastien
Antolin, Silvia
Yeo, Winnie
Bianchini, Giampaolo
Loi, Sherene
Tsurutani, Junji
Egorov, Anton
Liu, Yali
Cathcart, Jillian
Ashfaque, Shahid
Cortes, Javier
LANCET, 2023, 401 (10371): : 105 - 117

← 1 2 3 4 5 →